Table 2. Outcome following treatment with tepotinib in the long-term follow-up VISION clinical trial for cohorts A and C in treatment-naïve and previously treated patients, respectively.
| Outcome (IRC) | Cohort A | Cohort C | |||||
|---|---|---|---|---|---|---|---|
| Overall (N=152) |
Treatment-naïve (N=69) | Pretreated (N=83) |
Overall (N=161) |
Treatment-naïve (N=95) | Pretreated (N=66) |
||
| ORR, % (95% CI) | 46.7 (38.6–55.0) | 50.7 (38.4–63.0) | 43.4 (32.5–54.7) | 55.9 (47.9–63.7) | 62.1 (51.6–71.9) | 47.0 (34.8–59.7) | |
| DOR, months [median (95% CI)] | 15.4 (9.7–33.6) | 46.4 (7.2–NE) | 12.4 (8.4–18.5) | 20.8 (12.6–NE) | NE (13.4–NE) | 12.6 (5.1–NE) | |
| PFS, months [median (95% CI)] | 10.3 (8.2–12.7) | 10.3 (8.0–15.3) | 10.9 (8.2–12.7) | 13.8 (10.4–22.0) | 16.5 (10.4–NE) | 12.1 (6.9–24.9) | |
| OS, months [median (95% CI)] | 19.8 (15.2–22.9) | 19.1 (9.9–25.9) | 19.8 (15.0–22.3) | 19.3 (14.6–26.5) | 21.3 (13.7–32.7) | 18.0 (14.1–25.5) | |
The data in Table 2 are extracted from Mazieres et al. Supplemental Online Content (eTable 3 - Efficacy in Cohort C and Cohort A) (19). IRC, independent review committee; ORR, objective response rate; DOR, duration of response; PFS, progression-free survival; OS, overall survival; CI, confidence interval; NE, not estimable.